LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

Search

Lyell Immunopharma Inc

Abrir

0.4 -2.44

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.38

Máximo

0.41

Indicadores-chave

By Trading Economics

Rendimento

-147M

-192M

Vendas

-23K

11K

EPS

-0.172

Margem de lucro

-1,744,863.636

Funcionários

300

EBITDA

-12M

-58M

Recomendações

By TipRanks

Recomendações

Vender

Previsão para 12 meses

+138.1% upside

Dividendos

By Dow Jones

Próximos Ganhos

19 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-92M

125M

Abertura anterior

2.84

Fecho anterior

0.4

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Lyell Immunopharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 de mai. de 2025, 23:40 UTC

Conversa de Mercado

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 de mai. de 2025, 18:00 UTC

Ganhos

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 de mai. de 2025, 17:01 UTC

Principais Notícias

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 de mai. de 2025, 16:20 UTC

Ganhos

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 de mai. de 2025, 12:09 UTC

Principais Notícias

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 de mai. de 2025, 17:15 UTC

Principais Notícias

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 de mai. de 2025, 09:30 UTC

Principais Notícias
Ganhos

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 de mai. de 2025, 08:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de mai. de 2025, 08:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

16 de mai. de 2025, 23:18 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 de mai. de 2025, 22:30 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- Update

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 de mai. de 2025, 21:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de mai. de 2025, 21:54 UTC

Principais Notícias

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 de mai. de 2025, 21:22 UTC

Conversa de Mercado

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 de mai. de 2025, 21:17 UTC

Conversa de Mercado

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 de mai. de 2025, 21:17 UTC

Principais Notícias

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 de mai. de 2025, 21:05 UTC

Conversa de Mercado

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 de mai. de 2025, 20:55 UTC

Aquisições, Fusões, Aquisições de Empresas

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

16 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de mai. de 2025, 20:37 UTC

Principais Notícias

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 de mai. de 2025, 20:33 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 de mai. de 2025, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 de mai. de 2025, 20:18 UTC

Principais Notícias

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 de mai. de 2025, 20:16 UTC

Principais Notícias

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 de mai. de 2025, 20:15 UTC

Ganhos

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 de mai. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: William K. Daniel Joins Board

16 de mai. de 2025, 20:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Henry Schein: Strategic Investment by KKR Completed

Comparação entre Pares

Variação de preço

Lyell Immunopharma Inc Previsão

Preço-alvo

By TipRanks

138.1% parte superior

Previsão para 12 meses

Média 1 USD  138.1%

Máximo 1 USD

Mínimo 1 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Lyell Immunopharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Vender

2 ratings

0

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

0.4217 / 0.4691Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.